New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
Q&A: Maura Keefe and Alex Brill Discuss Understanding Drug Rebates and Their Role in Promoting Competition
Alex Brill, a senior fellow at the American Enterprise Institute and CEO of Matrix Global Advisors, recently sat down with CAPD spokesperson Maura Keefe to discuss his latest report for CAPD.
New PCMA Podcast Highlights Importance of Prescription Drug Rebates
“The rebate rule came out of a concern about rising drug prices,” said Brill. “But it is a policy that is chock full of unintended consequences. If it were implemented, we’d have fewer discounts. That’s definitely not going to lower overall spending in the healthcare sector.”
MGA Report Cited in Forbes Article on Rising Prescription Drug Prices
In his Forbes article, Ike Brannon discusses the blame game being played in Washington in regards to skyrocketing drug prices. MGA’s report “Understanding Drug Rebates and Their Role in Promoting Competition” was utilized by Brannon to bolster the argument that it is the drug companies who are responsible for drug pricing.
Patent Thickets Constrain US Biosimilars Market
Biosimilars represent a significant cost-savings opportunity in the United States because they can introduce competition for some of the most expensive and widely used prescription drugs on the market: originator biologics. Several market and regulatory barriers have slowed biosimilar market entry and uptake in the United States.
- Alex Brill Featured in Axios
- The Disparate State Impacts and Enormous Cost of a Gas Tax Holiday
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
